Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 19 participants, all of whom completed the study — none dropped out. The trial was testing a chemotherapy combination (oxaliplatin, gemcitabine, and bevacizumab) in women with a specific cancer, and it was measuring how many participants' disease responded to the treatment, how long participants went without their disease getting worse, how long participants survived after joining the study, and what kinds of side effects occurred. The reported data shows that 68.4% of participants (roughly 13 out of 19 women) had a "partial response" — meaning their disease showed a measurable reduction according to a standard set of assessment criteria. For the two survival measures, the reported data shows that, on average, participants went approximately 36.9 weeks before their disease progressed (got worse), and the average time participants were alive after joining the study was approximately 112.3 weeks. It is worth noting these are averages across a very small group of 19 people. Regarding side effects, the reported data shows that 94.7% of participants — nearly all of them — experienced side effects graded at level 2 or higher on a standard medical grading scale, where grade 2 roughly means a side effect noticeable enough to affect normal daily activities. The trial did not report a breakdown of which specific side effects occurred at what rates, so further detail on individual side effects is not available in this data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Ovarian Cancer Trial, Terminated
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with ovarian, fallopian tube, or primary peritoneal cancer that has come back, and your original diagnosis was confirmed by a lab test.
- You have at least one tumor that can be measured by scans, with each measurable area being larger than 20mm.
- You have at least one specific tumor area that doctors can track to see how well the treatment is working.
- Your cancer responded to platinum-based chemotherapy, and it has been at least 6 months since your last platinum treatment.
- You have had no more than two previous rounds of cancer treatment.
- You are in good enough general health to carry out daily activities with little or no restriction (confirm with trial site regarding the specific health scoring used).
- You are expected to live for at least 12 weeks or longer.
- You are 18 years of age or older.
- Your blood, kidney, liver, and nerve function are all within acceptable levels.
- Your blood clotting is functioning normally.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have received chemotherapy in the last 3 weeks.
- You are currently taking part in, have recently taken part in (within the last 4 weeks), or are planning to join another experimental drug study (with a possible exception for certain Genentech-sponsored studies — confirm with trial site).
- You have a known bleeding or blood clotting disorder, or have had a stroke.
- You have had a major surgery, open biopsy, or serious injury within the last 28 days, or are expected to need major surgery during the trial.
- You have had a minor surgical procedure within the last 14 days.
- You have significant heart disease, serious heart rhythm problems requiring medication, a history of blood clots in the veins, or significant circulation problems in your limbs within the past year.
- Your urine shows too high a level of protein relative to creatinine (confirm with trial site for exact levels).
- You have a history of, or current signs of, any disease affecting the brain or nervous system.
- You have had another type of cancer (other than certain common skin cancers) with signs of active disease in the last three years.
- You have had more than 2 previous courses of chemotherapy.
- You have previously been treated with a medication that targets a protein called VEGF (confirm with trial site).
- You have a wound, ulcer, or bone fracture that is not healing properly.
- You have previously had radiation treatment covering more than one-third of the areas in your body where blood cells are made.
- You have had abdominal fistulas, a hole in the bowel, an abscess in the abdomen, or a partial bowel blockage within the last 6 months.
- You are currently pregnant or breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Partial Response Rate
Other options
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.